05/12/14 - 10:19 AM EDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.READ FULL POST
05/08/14 - 09:05 AM EDT
Chelsea CEO Joe Oliveto and his team deserve a lot of credit for cleaning up some messy Northera clinical trials, scoring at the FDA advisory panel, securing the drug's approval and now delivering on the exit strategy that everyone wanted.READ FULL POST
05/07/14 - 12:49 PM EDT
Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug Xtandi.READ FULL POST
05/05/14 - 09:54 AM EDT
The Regeneron-Avalanche partnership and the hedge funds investment in the latter is more indirect evidence that Ohr Pharmaceuticals and its AMD eye drop Squalamine are not taken seriously.READ FULL POST
05/02/14 - 12:20 PM EDT
Her salary jumps to more than $1 million in 2013 from $300,000 in 2012, according to Questcor disclosure.READ FULL POST
05/02/14 - 10:58 AM EDT
Citizen Petition filed by Arena's partner Easai is denied by FDA.READ FULL POST
05/02/14 - 09:49 AM EDT
The biotech sector was down again, but there's some hopeful signs of a recovery.READ FULL POST
05/02/14 - 09:01 AM EDT
European regulators are likely to rescind the conditional approval of Endocyte's ovarian cancer drug Vynfinit following the failure of a phase III study.READ FULL POST
04/29/14 - 04:26 PM EDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.READ FULL POST
04/29/14 - 11:24 AM EDT
Two sell-side analysts with very different views Tuesday on Cytokinetics and its experimental ALS drug tirasemtiv.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.